MediWound Ltd.
MDWD · NASDAQ
Company research
MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, founded in 2000 and headquartered in Yavne, Israel. The company develops, manufactures, and commercializes innovative biologic solutions that leverage its proprietary proteolytic enzyme technology — derived from pineapple stems — to selectively remove non-viable tissue while preserving healthy tissue, offering a safer and more cost-effective alternative to traditional surgical debridement. Its FDA- and EMA-approved flagship product, NexoBrid®, is an orphan biologic used worldwide for eschar removal in patients with deep partial-thickness and full-thickness thermal burns, with over 16,000 patients treated globally and commercialized in North America through a strategic partnership with Vericel Corporation. Building on the same core enzymatic platform, MediWound is advancing EscharEx®, currently in Phase III development for the debridement of chronic wounds such as diabetic foot ulcers and venous leg ulcers, and MW005, an investigational topical therapy for low-risk basal cell carcinoma that has completed Phase I/II studies.
Research reports
Simply Wall St’s MDWD stock analysis, updated on 2026-06-21, highlights that analysts trimmed their fair value estimate from 25 to 22 after weaker Q1 revenues driven by reduced BARDA and Department of War grant contributions and constrained NexoBrid capacity, while still viewing EscharEx as a key driver of future sustained profitability. The report emphasizes that full-year revenue guidance and investor confidence hinge heavily on the timing and magnitude of BARDA-related revenue, creating a mixed outlook that balances long-term opportunity against near-term execution and funding risks.
StockInvest.us · July 25, 2025Mediwound Stock Forecast. Should You Buy MDWD?StockInvest.us provides a technical-analysis-based report dated 2025-07-25 that reviews MDWD’s recent price decline, trend structure, support and resistance levels, volume behavior, volatility, and a recommended stop-loss, concluding that despite a short-term sell signal from the moving average, the broader trend and multiple indicators point to MDWD as a “buy candidate” at current levels. The analysis forecasts an expected 7.68% price increase over the next three months with a projected trading range, framing the opportunity as medium risk due to average daily price swings and periods of low liquidity but still attractive for short-term traders seeking technical upside.